Literature DB >> 12196715

The role of neoadjuvant chemotherapy for breast cancer treatment.

Tadashi Ikeda1, Hiromitsu Jinno, Akira Matsu, Shigeru Masamura, Masaki Kitajima.   

Abstract

Neoadjuvant chemotherapy has become popular, especially for patients with advanced breast cancer. The pros and cons of neoadjuvant chemotherapy for treating breast cancer patients are reviewed. The advantages of neoadjuvant chemotherapy are 1) overall survival and recurrence-free survival rate are the same as post-operative chemotherapy, 2) serves as an in vivo sensitivity test, 3) increases the rate of breast conserving therapy, 4) facilitates the study of cancer biology. On the other hand, the disadvantages of neoadjuvant chemotherapy are 1) it modifies the stage, 2) treatment delay of PD cases, 3) residual intraductal component may be left behind after breast conserving surgery, 4) there are some cases of over-treatment. Combination chemotherapy is one possible way to increase the pathological CR rate, although the optimal order and cycles have not been determined. To avoid residual cancer cells after breast conserving surgery, the shrinkage pattern should be evaluated by MRI. Core needle biopsy should be performed before neoadjuvant chemotherapy to avoid over-treatment. It is essential to develop more effective regimens and stratify patients based on predictive factors.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12196715     DOI: 10.1007/bf02967540

Source DB:  PubMed          Journal:  Breast Cancer        ISSN: 1340-6868            Impact factor:   4.239


  6 in total

1.  Relationship between background parenchymal enhancement on breast MRI and pathological tumor response in breast cancer patients receiving neoadjuvant chemotherapy.

Authors:  Seon Jeong Oh; Eun Young Chae; Joo Hee Cha; Hee Jung Shin; Woo Jung Choi; Hak Hee Kim
Journal:  Br J Radiol       Date:  2018-06-05       Impact factor: 3.039

2.  [Neoadjuvant chemotherapy of breast carcinomas: what post-therapeutic (preoperative) information is provided by quantitative dynamic MRI?].

Authors:  K Wasser; S K Klein; H Junkermann; H P Sinn; S Darai; W Neff; H U Kauczor; S Delorme
Journal:  Radiologe       Date:  2007-05       Impact factor: 0.635

3.  Postmastectomy Radiotherapy After Neoadjuvant Chemotherapy in cT1-2N+ Breast Cancer Patients: A Single Center Experience and Review of Current Literature.

Authors:  Meng Luo; Huihui Chen; Hao Deng; Yao Jin; Gui Wang; Kun Zhang; Hong Ma; Yiding Chen; Suzhan Zhang; Jiaojiao Zhou
Journal:  Front Oncol       Date:  2022-05-17       Impact factor: 5.738

4.  The use of contrast-enhanced computed tomography before neoadjuvant chemotherapy to identify patients likely to be treated safely with breast-conserving surgery.

Authors:  Sadako Akashi-Tanaka; Takashi Fukutomi; Natsuko Sato; Eriko Iwamoto; Toru Watanabe; Noriyuki Katsumata; Masashi Ando; Kunihisa Miyakawa; Tadashi Hasegawa
Journal:  Ann Surg       Date:  2004-02       Impact factor: 12.969

5.  Impact of Postmastectomy Radiotherapy on Locoregional Control and Disease-Free Survival in Patients with Breast Cancer Treated with Neoadjuvant Chemotherapy.

Authors:  Yanyu Zhang; Yaotian Zhang; Zhuang Liu; Zilan Qin; Yubing Li; Jiaming Zhao; Xinchi Ma; Qiankun Yang; Ning Han; Xue Zeng; Hong Guo; Na Zhang
Journal:  J Oncol       Date:  2021-01-24       Impact factor: 4.375

6.  State of the art of neoadjuvant chemotherapy in breast cancer: rationale, results and recent developments.

Authors:  Arnd Honig; Lorenz Rieger; Marc Sutterlin; Diethelm Wallwiener; Johannes Dietl; Erich-Franz Solomayer
Journal:  Ger Med Sci       Date:  2005-09-13
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.